The currently available DKD therapies such as DPP-4 inhibitor (Gupta and Sen, 2019), SGLT-2 inhibitor (DeFronzo et al., 2021), ROCK inhibitors (Komers et al., 2011), ACEi and ARBs have been shown effective in combating DKD, but they could not completely prevent or reverse the progression of DKD (Kato and Natarajan, 2014; Wang et al., 2021). This evidence concerns the gene SLC5A2 and diabetic kidney disease.